ARCUS is an innovative technology platform that transforms medicines into light, dry powders. These powders are designed to deliver high doses of medication through an inhalation device that is activated by a patient’s own breath.

ARCUS doesn’t change a medicine’s molecules, but rather the size and shape of the particles. ARCUS particles can be up to 10x larger than traditionally inhaled medicine particles, but have a density that is up to 90% less, resulting in a powder that is more aerodynamically efficient than other dry powders. This allows more medicine to travel deep into the lungs. For more on ARCUS, view our fact sheet here.

We currently have one FDA-approved therapy that uses the ARCUS technology: to learn more click here.

The ARCUS technology has the potential to be used to develop additional inhaled medicines for both systemic and pulmonary conditions. We are working to identify a target in acute migraine appropriate for development, and are also working with the Bill & Melinda Gates Foundation to develop a dry powder version of lung surfactant, a treatment for neonatal respiratory distress syndrome.

Many Acorda associates have been working on ARCUS for over 20 years and research on ARCUS-based products continues at our Waltham, MA office. Commercial-scale manufacturing for ARCUS is conducted at our facility in Chelsea, MA.

ARCUS was initially developed in the lab of Robert S. Langer, Sc.D., David H. Koch Institute Professor at the Massachusetts Institute of Technology. Acorda obtained global rights as part of our acquisition of Civitas Therapeutics in 2014.

ARCUS® is a trademark of Acorda Therapeutics, Inc.